Navigation Links
ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
Date:6/3/2013

THOUSAND OAKS, Calif., June 3, 2013 /PRNewswire/ -- ImmunGene, Inc. today announced that pre‑clinical studies of its novel anti‑CD20 antibody-interferon alpha fusion protein, IGN002, demonstrated superior anti‑lymphoma activity against numerous cell lines in vitro and against established human xenograft tumors grown in mice. The findings were presented in the Developmental Therapeutics - Immunotherapy poster session on Saturday, June 1, at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago (abstract #3024).

"The unique combination of IGN002's potent anti-proliferative and direct apoptosis effects in addition to antibody‑dependent cellular cytotoxicity and enhanced complement-dependent cytotoxicity has not been seen with any other CD20‑targeted agent," stated John Timmerman , MD, Associate Professor of Medicine, University of California, Los Angeles (UCLA) Division of Hematology‑Oncology and senior author of the study.

The presentation highlights the rapid progress being made in the development of a new class of anti-cancer biotherapeutics which use antibody-interferon alpha fusion technology. This technology was developed by Sherie Morrison , PhD, Distinguished Professor of Microbiology, Immunology, and Molecular Genetics at UCLA. Part of the pre-clinical research for IGN002 has been done in collaboration with the laboratories of Timmerman and Morrison, who are members of UCLA's Jonsson Comprehensive Cancer Center, and funded by The Leukemia & Lymphoma Society, the UCLA/CalTech Joint Center for Translational Medicine, and the NIH/National Cancer Institute.

"Antibody‑fusion proteins are designed to be inactive at therapeutic doses in the bloodstream while highly potent in targeting and killing cancer cells. We believe this approach is likely to s
'/>"/>

SOURCE ImmunGene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
2. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
3. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
6. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
11. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Based On Naturally Resected tRNA Synthetases , ... subsidiary of aTyr Pharma in Hong Kong, today announced ... naturally occurring, resected human tRNA synthetases. Although tRNA ... machinery found in all organisms, human synthetases have naturally ...
... RICHMOND, Calif., June 29 Sangamo BioSciences, Inc. (Nasdaq: ... research milestone has been achieved in its Research and ... the Roche Group, for the generation of cell lines ... Sangamo,s proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. ...
Cached Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3
(Date:7/9/2014)... researchers reveal that sudden, acute episodes of low back ... temperature, humidity, air pressure, wind direction and precipitation. Findings ... journal of the American College of Rheumatology (ACR), indicate ... with higher wind speed or wind gusts, but was ... Health Organization (WHO) nearly everyone experiences low back pain ...
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... captures heretofore hidden ways that cells are regulated, scientists ... breast cancer cells more likely to metastasize. , What,s ... part by blocking two other proteins that are normally ... disease processes could have unexpected ties. , The ... Nature , points to the possibility of new ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have found ... who are also depressed have difficulty sticking to ... particularly true for women, and screening and brief ... of treatment. The study and its findings are ... , Chronic obstructive pulmonary disease is a ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... Bio-Pharmaceutical,Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer ... use in pharmaceutical,nutraceutical and food production, is pleased to ... month periods ended September 30, 2008. , ... that in the third quarter of 2008, Huifeng has,managed ...
... and TOKYO, Nov. 21 DATATRAK,International, Inc. (Nasdaq: ... company focused,on global eClinical solutions for the clinical ... Japan, NTT DATA Corporation, has placed its first,self-designed ... a Japanese clinical trial. The successful rollout ...
... 21 Vital Images, Inc.,(Nasdaq: VTAL ), ... Toshiba Medical Systems Corporation (Toshiba), have agreed to,renew their ... , As under ... its subsidiaries and distributors in more than 50 nations ...
... Patient Assistance ( www.PatientAssistance.com ) has released initial survey results ... ... Baton Rouge, LA – November 20, ... on diabetes awareness amongst the predominantly uninsured and underinsured visitors ...
... Anderson, was invited to participate with U.S. Secretary of Health, Michael ... , ... Salt Lake City (Vocus) November 20, 2008 -- ... Secretary of Health, Michael Leavitt, in the 2008 National Summit on ...
... "Super Dentist" award given to elite dentists in Texas. Dr. Michael ... the area of Cosmetic Dentistry. , ... Austin, TX ... was recently nominated as a "Texas Monthly Super Dentist" for ...
Cached Medicine News:Health News:Huifeng Bio-Pharmaceutical (HFGB) Reports Record Sales and Net Income 2Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 2Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 3Health News:Vital Images and Toshiba Renew Distribution Agreement 2Health News:Vital Images and Toshiba Renew Distribution Agreement 3Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 2Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 3Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2
Ophthalmic Nd Yag Laser with excellent quality optics for clear image and good laser delivery. Compact and light-weight for portability....
The compact size and portability of the Epic system makes it a cost-effective solution for single or multi-office use....
A conventional blue visibility-tinted daily-wear lens, custom made for astigmats with up to -3.00 D of cylinder requiring adds of up to +2.50 D....
A soft contact lens that lets presbyopes see clearly and comfortably at all distances , without the hassles of bifocals or reading glasses. Recommended for daily wear. Also approved for extended wear...
Medicine Products: